Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. Despite the frequent coexistence with coronary artery disease (CAD), the prognostic independent implication of AF in patients with stable CAD remains controversial. Our aim was to perform a pairwise meta-analysis of adjusted observational studies comparing cardiovascular outcomes in patients with stable CAD with and without concomitant AF, in search of AF-specific prognostic implications. We performed random effect meta-analysis of binary outcome events in studies comparing stable CAD patients with versus without AF providing risk estimates adjusted for confounding variables. Literature search was performed in PubMed/MEDLINE and Google Scholar. Death was the primary endpoint of the analysis, while myocardial infarction, coronary revascularization and stroke secondary endpoints. 5 studies were included in the meta-analysis, encompassing a total of 30230 stable CAD patients (2844 with AF, 27386 without AF). Stable CAD patients with AF presented an independent increased risk of death (HR 1.39, 95% CI: 1.17–1.66) and stroke (HR 1.88, 95% CI: 1.45–2.45) compared to those without AF. Instead, risk of myocardial infarction (HR 0.90, 95% CI: 0.66–1.22) and coronary revascularization (HR 0.96, 95% CI: 0.79–1.16) did not differ in stable CAD patients with and without the arrhythmia. In patients with stable CAD, AF exerts an independent negative prognostic effect, increasing the risk of death and stroke. However, the small number of eligible studies included in this analysis highlights the astonishing lack of data regarding prognostic implications of concomitant AF in patients with stable CAD.

Keywords
Stable coronary artery disease, Atrial fibrillation, Prognostic impact

1. Introduction
Atrial fibrillation (AF) is the most common tachyarrhythmia encountered in clinical practice [1]. Due to progressive population aging, the prevalence of this condition, currently settled at 2–4% worldwide, is deemed to double in the coming decades [1–4]. Coronary artery disease (CAD) frequently coexists with AF, and management of these associated conditions can be challenging [5]. In addition, AF may induce angina-like chest pain and increase markers of myocardial damage, even in the absence of classical CAD [6].

Despite the frequent coexistence of these two cardiac conditions, the prognostic independent implication of AF in patients with stable CAD remains controversial. In particular, although preclinical and clinical evidence suggests that AF itself may promote a reduction in coronary blood flow [7–11], less is known regarding the impact of the arrhythmia in stable CAD patients in terms of cardiac ischemic outcomes.

The aim of the present systematic review and meta-analysis of prospective adjusted observational studies is, therefore, to assess the prognostic independent impact of concomitant AF on stable CAD patients in terms of mortality, coronary events, and cerebrovascular events.

2. Methods
This systematic review and meta-analysis was performed in accordance with the PRISMA [12] and MOOSE [13] guidelines.

2.1 Search strategy and study selection
PubMed/MEDLINE and Google Scholar databases were screened for pertinent articles, using the following keywords: “coronary artery disease”, “stable”, “atrial fibrillation”, “death”, “myocardial infarction”, “stroke”, “coronary revascularization”. The search was ended in May 2019. Two independent reviewers (AS and VV) screened the retrieved citations through the title and/or abstract, and all disparities were resolved through consensus. Studies were included if they reported data from observational prospective studies describing the risk of all cause death (primary outcome) and/or other cardiovascular outcomes (myocardial infarction, coronary revascularization, stroke) in patients with stable CAD and AF vs patients without history of the arrhythmia, provided that the risk estimates were adjusted for possible confounding variables. Studies that did not fulfil the aforementioned study design criteria or in which data were not adequately reported were excluded from the analysis. Risk of bias evaluation of the included studies was performed using the Newcastle Ottawa Scale.
Continuous variables and categorical variables were reported as numbers and percentages, respectively. Median (interquartile range—IQR) was used for the summary statistics. Pairwise meta-analysis of adjusted hazard ratio (HR) of the evaluated endpoints in stable CAD patients with versus without AF was performed after logarithmic transformation using a random-effect model (inverse-variance weighting). Forest plots for each outcome were reported. Cochran I² test was used to assess heterogeneity in the included studies. Funnel plot analysis and Egger’s test for funnel plot asymmetry were used to assess potential publication bias. Statistical analyses were performed with R version 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria).

3. Results
The initial search identified 6888 potential studies: among these, 6749 were screened for possible inclusion, 6671 were excluded through title and abstract because not relevant to the topic, and 78 full-text articles were carefully reviewed (Fig. 1). Finally, 5 studies were included in the present systematic review and meta-analysis [14–18], encompassing 30230 stable CAD patients (2844 with AF, 27386 without AF). Table 1 (Ref. [14–18]) reports main characteristics of the studies, including the type of statistical adjustment used to control confounding. The median follow-up duration was 4.8 (IQR 4–4.9) years. Table 2 summarizes pooled baseline features of the meta-analytic population. The majority of patients were men (63.4% and 68.0%, in AF and non-AF patients, respectively) and median age was 69.2 and 64.1 years, in AF and non-AF patients, respectively. Median left ventricular ejection fraction was 52.8% and 56.6%, in AF and non-AF patients, respectively. Previous stroke/transient ischemic attack (TIA) history was present in 22.2% and 16.2%, in AF and non-AF patients, respectively. Previous myocardial infarction (MI), percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) were reported in 21.9% and 27.7%, 25.3% and 28.1%, and 6.8% and 5.2%, for AF and non-AF patients, respectively. All included studies showed low risk of bias according to Newcastle Ottawa Scale (Table 3, Ref. [14–18]).
Table 1. Main characteristics of the included studies.

| Study (first Author, year of publication) | Patients—n | AF—n (%) | Non-AF—n (%) | Follow-up (years) | Statistical adjustment |
|------------------------------------------|------------|----------|--------------|-------------------|-----------------------|
| Otterstad, 2006 [14]                     | 7665       | 313 (4.1)| 7352 (95.9)  | 4.9               | Adjusted Cox regression|
| Marte, 2009 [15]                         | 613        | 57 (9.3) | 576 (90.7)   | 4.0               | Adjusted Cox regression|
| Bouzas-Mosquera, 2010 [16]               | 17100      | 619 (3.6)| 16481 (96.4) | 6.5               | Adjusted Cox regression|
| Rohla, 2015 [17]                         | 1434       | 146 (10.2)| 1288 (89.8)  | 4.8               | Adjusted Cox regression|
| Han, 2018 [18]                           | 3418       | 1709 (50.0)| 1709 (50.0)  | 2.2               | Adjusted Cox regression|

n, number; AF, atrial fibrillation.

Table 2. Pooled baseline clinical features of the study population (30230 patients).

| Variables                      | Median value (lower–upper quartile) | AF group (N:2824) | Non–AF group (N:27406) |
|--------------------------------|-------------------------------------|-------------------|------------------------|
| Demographics                  |                                     |                   |                        |
| Age (years)                   | 64.3 (63.9–65.9)                    | 69.2 (67.9–70.7)  | 64.1 (63.3–65.0)       |
| Male sex (%)                  | 67 (62.8–72)                        | 63.4 (62.7–71.9)  | 68.0 (62.3–72.1)       |
| Coronary risk factors         |                                     |                   |                        |
| Hypertension (%)              | 51.8 (49.4–83.9)                    | 49.1 (49.0–83.6)  | 52.0 (49.4–84.0)       |
| Smoking (%)                   | 27.6 (20.7–39.7)                    | 16.9 (15.2–24.1)  | 28.7 (20.9–41.3)       |
| Diabetes (%)                  | 20.7 (15.6–29.7)                    | 16.0 (14.5–29.5)  | 21.0 (15.7–29.7)       |
| Dyslipidemia (%)              | 63.8 (56.2–71.2)                    | 60.1 (51.9–62.6)  | 63.8 (60.0–71.9)       |
| BMI                           | 27.5 (27.4–27.8)                    | 27.3 (26.7–27.7)  | 27.5 (27.5–27.8)       |
| Comorbidities                 |                                     |                   |                        |
| Heart failure (%)             | 8.9 (5.6–18.2)                      | 27.3 (17.2–27.7)  | 6.8 (4.2–17.2)         |
| Ejection fraction             | 56.3 (52.6–61.7)                    | 52.8 (50.2–53.4)  | 56.6 (52.8–62.3)       |
| Previous stroke/TIA (%)      | 17.0 (12.4–21.5)                    | 22.2 (20–24.3)    | 16.2 (11.5–20.8)       |
| Peripheral artery disease (%) | 10.4 (8.7–12.2)                     | 10.9 (9.2–12.5)   | 10.2 (8.4–12.0)        |
| Chronic kidney disease (%)   | 23.4 (16.4–30.5)                    | 30.2 (19.8–40.6)  | 23.1 (16.1–30.0)       |
| Previous coronary events     |                                     |                   |                        |
| MI (%)                        | 27.1 (22.2–39.2)                    | 21.9 (18.4–39.5)  | 27.7 (22.6–39.4)       |
| PCI* (%)                      | 27.8 (18.5–36.5)                    | 25.3 (16.2–36.7)  | 28.1 (18.6–36.6)       |
| CABG (%)                      | 5.4 (4.2–6.5)                       | 6.8 (5.3–8.2)     | 5.2 (4.1–6.4)          |
| Antithrombotic therapy        |                                     |                   |                        |
| Antiplatelet agent (%)        | 89.3 (66.8–98.8)                    | 73.0 (52.5–85.9)  | 90.0 (79.5–94.7)       |
| Anticoagulant therapy (%)     | 5.12 (3.98–6.26)                    | 33.9 (29.3–45.5)  | 3.0 (2.6–3.1)          |

* Number of patients who had undergone to PCI before enrolment in the study.

BMI, Body Mass Index; CABG, coronary artery bypass graft; MI, myocardial infarction; PCI, percutaneous coronary intervention.

All five included studies evaluated the primary outcome, while two studies reported adjusted risk estimates for stroke, three for myocardial infarction and two for coronary revascularization. Details on the adjustment performed in each study are reported in Supplementary Table 1 in the Supplementary Material. Pooled analysis of adjusted observational results indicates an increased risk of death in stable CAD patients with concomitant AF, compared to stable CAD patients without the arrhythmia (HR 1.39, 95% CI: 1.17–1.66). Low degree of heterogeneity was found for this outcome ($I^2 = 35\%$), and funnel plot analysis (Supplementary Fig. 1) did not suggest potential publication bias (Egger’s test $p$-value 0.28). Fig. 2 reports the forest plot for the primary outcome. Focusing on secondary outcomes (Fig. 3 and Supplementary Figs. 2–4), AF independently increased the risk of stroke in this group of patients (HR 1.88, 95% CI: 1.45–2.45, $I^2 = 0\%$). Instead, risk of myocardial infarction (HR 0.90, 95% CI: 0.66–1.22, $I^2 = 25\%$) and coronary revascularization (HR 0.96, 95% CI: 0.79–1.16, $I^2 = 0\%$) did not differ in stable CAD patients with or without AF.

4. Discussion

The main findings of the present systematic review and meta-analysis are the following:

- AF independently increases the risk of death in patients with stable CAD by 39%.
- Patients with stable CAD and concomitant AF have nearly twofold increase in risk of stroke (+88%) compared to patients with stable CAD without AF.
- AF does not seem to result into an increased risk of classical defined coronary events (myocardial infarction and coronary revascularization).

AF and CAD are two frequently coexisting conditions, sharing common risk factors, such as age, hypertension, dia-
Death

| Study              | TE  | SE  | Weight | Hazard Ratio |
|--------------------|-----|-----|--------|--------------|
| Otterstad 2006     | 0.35| 0.1641| 19.5%  | 1.42 [1.03; 1.96] |
| Marte 2009         | 0.99| 0.4935| 3.0%   | 2.68 [1.02; 7.05] |
| Bouzas–Mosquera 2010 | 0.37| 0.0977| 34.4%  | 1.45 [1.20; 1.76] |
| Rohia 2015         | 0.52| 0.2026| 14.4%  | 1.68 [1.13; 2.50] |
| Han 2018           | 0.11| 0.1190| 28.6%  | 1.12 [0.88; 1.41] |
| Total (95% CI)     |     |     |        | 100.0% 1.39 [1.17; 1.66] |

Heterogeneity: Tau² = 0.0132; Chi² = 6.19, df = 4 (P = 0.19); I² = 35%

Fig. 2. Forest plot for the primary outcome (death).

Stroke

| Study              | TE  | SE  | Weight | Hazard Ratio |
|--------------------|-----|-----|--------|--------------|
| Otterstad 2006     | 0.43| 0.2956| 20.8%  | 1.54 [0.86; 2.75] |
| Han 2018           | 0.68| 0.1513| 79.2%  | 1.98 [1.47; 2.67] |
| Total (95% CI)     |     |     |        | 100.0% 1.88 [1.45; 2.45] |

Heterogeneity: Tau² = 0; Chi² = 0.58, df = 1 (P = 0.45); I² = 0%

Myocardial infarction

| Study              | TE  | SE  | Weight | Hazard Ratio |
|--------------------|-----|-----|--------|--------------|
| Otterstad 2006     | 0.16| 0.2061| 39.7%  | 1.17 [0.78; 1.75] |
| Bouzas–Mosquera 2010 | -0.26| 0.1863| 45.5%  | 0.77 [0.53; 1.11] |
| Han 2018           | -0.32| 0.3797| 14.9%  | 0.72 [0.34; 1.52] |
| Total (95% CI)     |     |     |        | 100.0% 0.90 [0.66; 1.22] |

Heterogeneity: Tau² = 0.0185; Chi² = 2.65, df = 2 (P = 0.27); I² = 25%

Coronary Revascularization

| Study              | TE  | SE  | Weight | Hazard Ratio |
|--------------------|-----|-----|--------|--------------|
| Bouzas–Mosquera 2010 | 0.05| 0.1441| 45.5%  | 1.05 [0.79; 1.39] |
| Han 2018           | -0.12| 0.1317| 54.5%  | 0.89 [0.68; 1.15] |
| Total (95% CI)     |     |     |        | 100.0% 0.96 [0.79; 1.16] |

Heterogeneity: Tau² = 0; Chi² = 0.76, df = 1 (P = 0.38); I² = 0%

Fig. 3. Forest plots for secondary outcomes (stroke, myocardial infarction and coronary revascularization).
Table 3. Risk of bias evaluation using the Newcastle-Ottawa Scale (NOS).

| Study (first Author, year of publication) | NOS domains |
|------------------------------------------|-------------|
| Otterstad, 2006 [14]                     | **** ** *** |
| Marte, 2009 [15]                         | **** ** *** |
| Bouzas-Mosquera, 2010 [16]               | **** ** *** |
| Rohila, 2015 [17]                        | **** ** *** |
| Han, 2018 [18]                           | **** ** *** |

Asterisks indicate the star rating according to the Newcastle-Ottawa Scale. Good quality is defined with: 3–4 stars in “Selection” and 1–2 stars in “Comparability” and 2–3 stars in “Outcome”. Fair quality is defined with: 2 stars in “Selection” and 1–2 stars in “Comparability” and 2–3 stars in “Outcome”. Poor quality is defined with: 0–1 stars in “Selection” or 0 stars in “Comparability” or 0–1 stars in “Outcome”.

Volume 22, Number 2, 2021 443

The present analysis shows, in any case, that AF has an independent prognostic influence in patients with stable CAD, conferring an additional 39% risk of death, as well as an 88% additional risk of incident stroke. Being CAD a risk factor for stroke and death per se, this relationship entails an even greater risk for these complications compared to AF alone. On the other hand, interestingly, AF does not appear to confer a worse CAD related outcome. However, before drawing definite conclusion about this relationship, it must be taken into account the small number of studies included into the analysis, which could entail statistical underpowering on the topic.

Future studies are warranted to reach definitive conclusions on this topic. Moreover, evidence is needed investigating the effect of the AF related “irregularly irregular” rhythm on the coronary circulation, both in terms of acute hemodynamic data than potential pro-atherogenic effect.

5. Limitations
First, the observational design of the included studies carries an inherent risk of unaccounted confounders. In addition, the lack of patient-level data limited establishing eventual prognostic implications of the specific AF subtype (paroxysmal, persistent, permanent). Moreover, data on the safety profile of a combined therapy with anticoagulant and antiplatelet agents are missing and considerations on this regard were not possible. Finally, the restricted number of studies evaluating cardiovascular outcomes other than death, limits inferential power to detect potentially significant differences in these outcomes among groups of interest.

6. Conclusions
In patients with stable CAD AF exerts an independent negative prognostic effect, increasing the risk of death and stroke. However, the small number of eligible studies included in this analysis highlights the astonishing lack of data regarding prognostic implications of concomitant AF in patients with stable CAD, stressing the need for future studies focused on this topic, as well as on the hemodynamic effects exerted by the arrhythmia on the coronary circulation.

Author contributions
AS, VV and MA designed the research study and conducted the literature search. AS and VV drafted the manuscript. AB, HX, GMD and MA helped draft and critically revised the manuscript.

Acknowledgment
We would like to express our gratitude to all the peer reviewers for their opinions and suggestions.

Funding
This research received no external funding.

Conflict of interest
The authors declare no conflict of interest.

Supplementary material
Supplementary material associated with this article can be found, in the online version, at https://rcm.imrpress.com/E N/10.31083/j.rcm2202049.

References
[1] Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American heart association. Circulation NLM. 2019; 139: e56-e528.
[2] Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation. Circulation. 2014; 129: 837–847.
[3] Colilila S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. The American Journal of Cardiology. 2013; 112: 1142–1147.
[4] Krijthe BP, Kunst A, Benjamin EJ, Lip GYH, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. European Heart Journal. 2013; 34: 2746–2751.
[5] Michniewicz E, Młodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease - Double trouble. Advances in Medical Sciences. 2018; 63: 30–35.

[6] Smit MD, Tio RA, Slart RHJA, Zijlstra F, Van Gelder IC. Myocardial perfusion imaging does not adequately assess the risk of coronary artery disease in patients with atrial fibrillation. Europace. 2010; 12: 643–648.

[7] Range FT, Paul M, Schäfers KP, Acil T, Kies P, Hermann S, et al. Myocardial perfusion in nonischemic dilated cardiomyopathy with and without atrial fibrillation. Journal of Nuclear Medicine. 2009; 50: 390–396.

[8] Range FT, Schäfers M, Acil T, Schäfers KP, Kies P, Paul M, et al. Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation. European Heart Journal. 2007; 28: 2223–2230.

[9] Kochiadakis GE, Skalidis EI, Kalebubas MD, Igoumenidis NE, Chrysostomakis SI, Kanoupakis EM, et al. Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans. European Heart Journal. 2002; 23: 734–741.

[10] Wichmann J, Ertl G, Rudolph G, Kochsiek K. Effect of experimentally induced atrial fibrillation on coronary circulation in dogs. Basic Research in Cardiology. 1983; 78: 473–491.

[11] Saito D, Haraoka S, Ueda M, Fujimoto T, Yoshida H, Ogino Y. Effect of atrial fibrillation on coronary circulation and blood flow distribution across the left ventricular wall in anesthetised open-chest dogs. Japanese Circulation Journal. 1978; 42: 417–423.

[12] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. British Medical Journal. 2009; 339: b2700.

[13] Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. The Journal of the American Medical Association. 2000; 283: 2008–2012.

[14] Erik Otterstad J, Kirwan B, Lubesn J, De Brouwer S, Fox KAA, Corell P, et al. Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease. Scandinavian Cardiovascular Journal. 2006; 40: 152–159.

[15] Marte T, Saely CH, Schmid F, Koch L, Drexel H. Effectiveness of atrial fibrillation as an independent predictor of death and coronary events in patients having coronary angiography. The American Journal of Cardiology. 2009; 103: 36–40.

[16] Bouzas-Mosquera A, Peteiro J, Broullón EJ, Alvarez-Garcia N, Mosquera VX, Casas S, et al. Effect of atrial fibrillation on outcome in patients with known or suspected coronary artery disease referred for exercise stress testing. The American Journal of Cardiology. 2010; 105: 1207–1211.

[17] Rohla M, Vennekate CK, Tentzeris I, Freynhofer MK, Farhan S, Egger F, et al. Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease. International Journal of Cardiology. 2015; 184: 108–114.

[18] Han S, Park G, Kim Y, Hwang KW, Roh J, Won K, et al. Effect of atrial fibrillation in Asian patients undergoing percutaneous coronary intervention with drug-eluting stents for stable coronary artery disease. Medicine. 2018; 97: e13488.